Key blockbuster drugs about to get generic rivals

    These are blockbuster drugs, with more than $1 billion in annual global sales, set to go off patent and get generic competition in the U.S. in the next two years:


    Note: Patent expiration/generic arrival dates can change due to litigation or regulatory issues.

    Sources: Medco Health Solutions Inc., company Web sites.